Peptide storage: lyophilized vs reconstituted, and what actually degrades

A peptide vial leads two lives. Dry — lyophilized into a solid cake and sealed — it is one of the more durable forms a fragile molecule can take, which is why it crossed the country in a padded envelope with no ice. Reconstituted, it is on a clock that runs one direction. By the end of this article you will know the chemistry behind that split: where each state of the vial belongs once you own it, what "degradation" actually means at the molecular level, what bacteriostatic water does and does not protect against, and what the community's 28-day rule actually is — a borrowed convention, not measured stability data.

Why the vial shipped without a cold pack

Lyophilization — freeze-drying — removes water from a frozen solution by sublimation, leaving the peptide as a porous solid cake. That matters because water enables the two fastest degradation routes: it is a direct chemical reactant in hydrolysis, and it is the solvent that gives molecules enough mobility to react at all. Remove the water and most degradation chemistry slows from a timescale of days or weeks to months or years. Lai and Topp's review of solid-state peptide and protein stability in the Journal of Pharmaceutical Sciences is the standard reference for how much slower solid-state chemistry runs.

This is why a sealed lyophilized vial can spend three summer days in a delivery truck and arrive essentially intact. The exposure costs some small, unmeasured fraction of shelf life — heat is a rate problem, not a cliff.

Be precise about the epistemic status, though. "Generally fine short-term" is solid-state chemistry plus industry practice, not a stability study on the specific vial in your hands. Three days in transit and three weeks in a hot mailroom are different bets, and nobody has measured either for a gray-market vial.

The storage hierarchy once it's yours

The freezer figure for lyophilized vials is supplier convention for research peptides — consistent with the solid-state chemistry above, but not a per-compound measurement. The fridge rule for reconstituted vials is borrowed directly from how every approved injectable peptide is labeled: cold, dark, and for a limited time.

The organizing fact is simple. The moment water enters the vial, all three degradation mechanisms wake up. Everything you do after reconstitution is about slowing them down.

What degradation actually is

"Degraded" is not one thing. Three mechanisms account for most peptide loss, and they respond to different conditions. Manning and colleagues' survey of protein pharmaceutical stability in Pharmaceutical Research is the standard map of all three.

Hydrolysis is water attacking the molecule directly. It clips the peptide backbone — aspartate–proline linkages are notably fragile — and converts side chains, most famously the deamidation of asparagine. The product is a molecule that is almost, but not quite, the one that was in the vial, and "almost" can mean reduced or zero activity.

Oxidation hits the vulnerable side chains: methionine, cysteine, and tryptophan. It is driven by dissolved oxygen, trace metals, peroxides, and light — which is why light protection appears on essentially every injectable peptide label.

Aggregation is physical rather than chemical. Peptide molecules unfold slightly and stick to one another, encouraged by heat, shaking and foaming, freeze–thaw, and contact with air–liquid interfaces. At the visible extreme it shows up as cloudiness or particles. Aggregates are inactive, and in protein drugs they are the degradation product most associated with unwanted immune responses (Rosenberg's review in the AAPS Journal is the reference point).

None of this makes a degraded vial acutely dangerous by default — the main cost is potency you cannot verify. But it is why "it's probably fine" and "it's what it was" are different claims, and why a solution that has changed appearance is not worth arguing with.

What bacteriostatic water enables — and what it doesn't

Bacteriostatic water is water for injection plus 0.9% benzyl alcohol, per its FDA label. The benzyl alcohol inhibits bacterial growth inside the vial, and that is the entire mechanism behind multi-dose use: every needle puncture through the septum is a chance to introduce organisms, and the preservative keeps a small inoculum from becoming a colony between doses. How much of it to add is a separate, purely arithmetic question — that one belongs to the bacteriostatic water calculator.

Be equally clear about the limits. Benzyl alcohol does nothing for chemical stability — hydrolysis, oxidation, and aggregation proceed exactly as fast with it as without it. It is bacteriostatic, not a sterilant: it cannot rescue a vial contaminated by poor technique or a non-sterile source. And it carries one hard exclusion from its own label: benzyl alcohol is toxic to newborns (the "gasping syndrome" warning), which is why preserved diluents are never used in neonates.

Plain sterile water for injection, by contrast, contains no preservative, and its label posture is single-use: discard the remainder. Reconstituting with it and then drawing from the vial for weeks quietly imports multi-dose behavior without the one protection that justifies it.

Freeze–thaw: the one cold that hurts

Freezing feels like it should preserve a reconstituted vial even harder than the fridge. It does the opposite. As ice crystals form, everything dissolved in the shrinking liquid phase — peptide, salts, preservative — concentrates dramatically, and the growing ice surface is itself an interface that unfolds peptide molecules. Thawing does not undo the damage, and every repeat cycle runs the stress again. Freeze–thaw is one of the classic aggregation triggers in the protein-stability literature.

The approved products compress this into one line. The Ozempic label: do not freeze, and do not use it if it has been frozen. The logic generalizes cleanly — freezer for the dry cake, fridge for the solution, and never back and forth.

Light and heat

Light drives photooxidation of tryptophan, tyrosine, and methionine residues, which is why "protect from light" appears on injectable peptide labels and why pens are stored with the cap on. A closed box in the fridge beats amber glass on a counter; darkness is cheaper than chemistry.

Heat is a rate multiplier. The rule of thumb that pharmaceutical accelerated-stability testing is built on is that reaction rates roughly double for every 10 °C increase. A reconstituted vial living on a sunny windowsill is running its own accelerated-degradation study, uninstrumented.

What the FDA-labeled products do

The labels of approved injectable peptides are the closest thing that exists to regulator-reviewed, measured stability data, and they all follow the same shape: refrigerate before first use, then a fixed and finite window after.

Semaglutide as Ozempic is the clearest example. Before first use: refrigerate at 36–46 °F (2–8 °C). After first use: 56 days, at room temperature (59–86 °F) or refrigerated, then discard regardless of what remains. Do not freeze; protect from light. Note that Ozempic is a preserved multi-dose pen — the formulation includes phenol — and its measured after-first-use window is 56 days, not 28.

Tirzepatide as Mounjaro shows the other pattern: refrigerated storage with a labeled allowance of up to 21 days at room temperature not exceeding 86 °F. Mounjaro is a single-dose product with no preservative — which is precisely why it is single-dose.

The template to borrow from both: cold by default, a defined window once in use, a hard stop at the end of it, light protection throughout. A gray-market vial of BPC-157 — not FDA-approved, sold as a research chemical — arrives with no such label because nobody ran those studies for it. The storage discipline transfers; the measured numbers do not exist.

Where "28 days" actually comes from

The community convention — a reconstituted vial is good for 28 days in the fridge — is borrowed from multi-dose vial rules in clinical practice. USP General Chapter <797> and CDC injection-safety guidance both set a default beyond-use date of 28 days after first puncture for preserved multi-dose vials, unless the manufacturer specifies otherwise.

Read that carefully, because both halves matter.

First, it is a microbial-risk convention. The 28-day figure limits contamination exposure in a punctured, preserved vial. It was never a measurement of any peptide's chemical stability — a vial abused with heat and light can be meaningfully degraded by day 3, and a cold, dark one may be chemically fine well past day 28. Nobody has measured either for the vial in your fridge.

Second, it assumes a preservative is present. Bacteriostatic water is what carries the convention's premise into a research vial. Reconstitute with plain sterile water and the 28-day logic never applied to begin with.

So the honest epistemic status is: a reasonable, conservative default borrowed from pharmacy practice — not stability data for your compound, your concentration, or your vial. The instructive comparison is Ozempic's 56-day window, which was measured for that specific formulation and reviewed by FDA. When nobody has measured yours, the borrowed convention is what is left, and it at least errs in the safe direction.

Sources

• Ozempic (semaglutide) prescribing information, Novo Nordisk — storage and handling; formulation.
• Mounjaro (tirzepatide) prescribing information, Eli Lilly — storage and handling.
• Bacteriostatic Water for Injection, USP — FDA label (0.9% benzyl alcohol; neonatal warning).
• USP General Chapter <797>, Pharmaceutical Compounding — Sterile Preparations — beyond-use dating for multi-dose containers.
• CDC injection safety guidance — multi-dose vial dating and handling.
• Manning, Chou, Murphy, Payne, Katayama. Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 2010.
• Lai, Topp. Solid-state chemical stability of proteins and peptides. Journal of Pharmaceutical Sciences, 1999.
• Wang. Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics, 2000.
• Rosenberg. Effects of protein aggregates: an immunologic perspective. AAPS Journal, 2006.